



## Sequelae following an epidemic of meningococcal meningitis in Niger

Abdoul-Aziz Idrissa, Salifou Atti, Roger Kiamvu Wasaulua, Serge Kazadi, Ousmane Guindo, Georges Tonamou, Iza Ciglonecki, Matthew E Coldiron

# Introduction – 2022 meningitis epidemic in Magaria and Dungass

Epidemics of Serogroup C *Neisseria meningitidis* (NmC) in area in 2020 and 2021

2022 epidemic ran between November 2021 and April 2022

MSF supported Ministry of Public Health

- Case management
- Reactive vaccination campaign (March 2022)



This map is for information purposes only and has no political significance / Cette carte est exclusivement à but informatif et n'a aucune signification politique

# Introduction – Burden of meningitis sequelae

1 in 5 bacterial meningitis survivors have enduring after-effects<sup>1</sup>

- Deafness, epilepsy, paralysis, cognitive impairment, limb amputation
- Pneumococcal and Hib meningitis > meningococcal meningitis

Costs to patients and their families

- Acute illness
- Long-term aftercare costs and opportunity costs related to caregiving<sup>2</sup>

Meningitis increases health disparities

- Poorest are most vulnerable to meningitis
- Women and girls disproportionately serve as caregivers

<sup>1</sup>Edmond K et al, Lancet Infect Dis 2010;10:317-28

<sup>2</sup>Edmond K et al, Pediatr Infect Dis J 2010;29:1023-29

# Introduction – Defeating Meningitis 2030 Roadmap




## Strategic goals related to sequelae:

- “Strengthen early recognition and management of sequelae from meningitis in health care and community settings”
- “Increase the availability of and access to appropriate care and support for: (i) people affected by meningitis; (ii) their families and carers”

## Today’s reality:

- Evaluation of sequelae not a part of epidemic response
- Resources for aftercare are scarce and often not integrated into curative healthcare system
- Paucity of data from sub-Saharan Africa perpetuates the problem → MSF wants to contribute to change

## 5 overlapping pillars of the roadmap



# Survey methods

WHO case definitions used during epidemic

District Health authorities provided linelists

- PCR results from national reference lab
- Patients sorted by village of origin

Survey nurses attempted to locate patients using local guides in October 2022

- Patients (or surviving relatives) provided written consent

Ethics review by MSF-ERB and CNERIS of Niger

## Questionnaire topics

- Household composition
- Vaccination status / use of antibiotic prophylaxis in household
- Health seeking behavior
- Additional meningitis cases in household
- Vital status / timing of death
- Self-reported sequelae (hearing and vision loss, seizures, cognitive problems)
- Physical exam (anosmia, paralysis, weakness)

# Results – Epidemic description

## Overall epidemic

1001 cases reported in 230 distinct villages

470 cerebrospinal fluid (CSF) samples received at national reference laboratory

220 (47%) positive for bacterial cause by PCR

- 192 NmC
- 22 *S. pneumoniae*
- 3 *H. influenzae* serotype b
- 3 NmX

50 deaths (CFR 5.0%)

# Results – Epidemic description

## Overall epidemic

1001 cases reported in 230 distinct villages

470 cerebrospinal fluid (CSF) samples received at national reference laboratory

220 (47%) positive for bacterial cause

- 192 NmC
- 22 *S. pneumoniae*
- 3 *H. influenzae* serotype b
- 3 NmX

50 deaths in linelist (CFR 5.0%)

## Surveyed patients

Attempted to locate 919 – excluded distant villages reporting only 1 case

570 cases found (62% of target), of whom 356 had had CSF samples sent to lab during epidemic


165 (45%) positive for bacterial cause

- 149 NmC
- 10 *S. pneumoniae*
- 3 *H. influenzae* serotype b
- 3 NmX


49 deaths (CFR 8.6%)

# All notified cases during the epidemic

## Magaria




## Dungass




# All notified cases during the epidemic

## Magaria




# Cases enrolled in the survey


## Magaria



## Dungass



## Dungass



## Results – Prevalence of sequelae

61 of 521 (12%) surviving cases had  $\geq 1$  sequela

25 of 138 (18%) surviving confirmed cases of NmC had  $\geq 1$  sequela

Age in years	Number of cases surveyed	Number of cases (%) with sequelae
0-1	59	7 (12)
2-4	117	16 (14)
5-14	257	27 (11)
15-29	64	9 (14)
30-44	17	2 (12)
$\geq 45$	7	0

## Results – Selected details about the sequelae

Sequela	Number of cases	Prevalence among survivors (%)
Hearing loss / deafness	29	5.6
Paralysis	15	2.9
Epilepsy	9	1.7
Cognitive troubles	6	1.2
Severe headache	4	0.8
Skin lesions	4	0.8

### Hearing loss/deafness

- Median age 10 years old [IQR 4-15]

### Paralysis

- Mix of paraplegia, hemiplegia and isolated limb paralysis

### Epilepsy

- 7/9 cases were in children <10 years

# Limitations

Not necessarily representative sample of all meningitis patients during epidemic

Predominantly meningococcal meningitis epidemic – conclusions not necessarily the same for other meningitis pathogens, or for sporadic cases

No pre- and post- measurements of hearing loss or cognitive function

Self-reporting of hearing loss may have missed more subtle cases, particularly in younger children

# Conclusions

Severe sequelae were common among meningitis survivors

- Results concordant with previous survey after an NmC epidemic in Niger in 2015<sup>3</sup>

No long-term care was offered to survivors with sequelae during/after this epidemic

- MSF now searching for disability care partners in Niger

Inclusion of aftercare for meningitis survivors requires re-thinking models of care

- Justice, equity, and patient-centeredness
- Solutions will not be easy – but we need to keep meningitis aftercare on agenda

# Acknowledgements

Patients and their families

Village leaders and community health agents  
in the Magaria and Dungass Districts

Ministry of Public Health collaborators in  
Magaria, Dungass, Zinder and Niamey

MSF and Epicentre teams in Magaria and  
Maradi



Photo ©MSF/Elise Mertens